BiotechTube
Home/Janux Therapeutics/Tommy DiRaimondo, Ph.D.
TD

Tommy DiRaimondo, Ph.D.

Chief Scientific Officer

Janux Therapeutics

Therapeutic Areas

OncologyAutoimmune Diseases

Janux Therapeutics Pipeline

DrugIndicationPhase
JANX007Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 1
JANX008EGFR-positive Solid TumorsPhase 1
JANX011Autoimmune DiseasesPhase 1
PSMA-TRACIrmCRPCIND-Enabling
Merck TRACTr Program 1UndisclosedPhase 1
Merck TRACTr Program 2UndisclosedDiscovery
BMS TRACTr ProgramUndisclosedDiscovery

Leadership Team at Janux Therapeutics

DC
David Campbell, Ph.D.
Founder, President & Chief Executive Officer
WG
William Go, M.D., Ph.D.
Chief Medical Officer
JD
Janeen Doyle
Chief Corporate and Business Development Officer
CW
Charles Winter
Chief Technical Officer
CC
Carolina Caffaro, Ph.D.
Vice President, CMC Process Development
JD
Jenna Daly
Vice President, Clinical Operations
JP
James Pennington
General Counsel
RB
Ron Barrett, Ph.D.
Chairperson of the Board
ED
Eric Dobmeier, J.D.
Board Member
SG
Sheila Gujrathi, M.D.
Board Member
View full Janux Therapeutics profile